Good morning, everyone, and thank you for attending this quarterly call for 2024. Uh, could I have the next slide, please? Which is the disclaimer. The classical disclaimer is that we will not go through the next slide. So together with me, we have Johnny Stilou, our CFO, and I will quickly go through the clinical updates. Then Johnny will go through the financial performance, and then I will update you about our partnering activities. Next slide, please. Yes. All right. So you can see us. Next slide. Right. So, as most of you likely know, we are involved in Colorectal Cancer. We are a drug resistance company. One of the first companies actually in this setting. And we have, over the last few years, engaged in a program called CORIST. And, with our compound, our lead compound, SCO-101, which is a small molecule combined with FOLFIRI, we've advanced from phase one to phase two, and now we are in phase two A. We are certainly expecting the final data to be released early. In 2025, we released the top-line data, which are positive phase 2A data. And we will be releasing the final data analysis early in 2025. So, for colorectal cancer, this pertains to the CORIST program. And I will go into more details later on.
PANTAX is our clinical trial in pancreatic cancer. This is a phase 1B. We have released the data earlier this year that show good tolerability, good safety with a combination of nab-paclitaxel and gemcitabine and, of course, SCO-101. At the same time, you know, we engaged earlier in gastric cancer and have been able to release some good preclinical data for this indication. Therefore, we are ready to engage in a phase 1B2A. At the same time, mainly due to cost constraints, we have not been able to continue the preclinical development program with SCO-201. But this is certainly an asset that could also potentially be used in other indications beyond oncology, like HIV, and that asset is currently on hold from a preclinical development perspective. Should I have the next slide, please? Right. So here are a bit more details about CORIST. So we've been able to release the top-line data earlier in the year. We've been able to demonstrate a good safety and tolerability profile. Something which is very important in oncology is, of course, partial responses. And in the last cohort where we've been able to demonstrate our MTD, we have got two PRs. And this is extremely encouraging for us and for the patients. Of course, at the same time, we've been able to show a significant overall survival, which is in the range of 8 to 10 months. And also, if we are selecting a subgroup of patients expressing one type of UGT1A1, then we've been able to increase the overall survival up to 13 months, which is significant. I know, of course, that this is based on a limited set of patients, but at least we have to start somewhere. And obviously, this can only be encouraging for the future development of our clinical trial. So the conclusion is that we've been able to achieve an MTD (maximum tolerated dose) for the four-day schedule using SCO-101 in combination with FOLFIRI, meaning that we have 50% oenothera dosage and 100% Leucovorin and 5-FU. And then the result is that we have an MTD at 250 mg per day of SCO-101. So altogether, this is extremely encouraging for continuing the development of our clinical development plan for colorectal cancer with SCO-101. Next slide, please. So this is for Johnny. Johnny, please go ahead.